Lowering risk without lowering cholesterol: Implications for national cholesterol policy

Annals of Internal Medicine

Volumn 125, Issue 6, 1996, Pages 502-506

  Avins, Andrew L ^a,b   Browner, Warren S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT;

ADULT; CORONARY ARTERY DISEASE; DRUG COST; ECONOMICS; ESTROGEN THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW; RISK FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CORONARY DISEASE; DRUG COSTS; ESTROGEN REPLACEMENT THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 0030587237     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-6-199609150-00012     Document Type: Article

References (22)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23.
2. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988;148:36-69.
3. Davey-Smith G. Egger M. Who benefits from medical interventions? [Editorial] BMJ. 1994;308:72-4.
4. McDowell A. Plan and operation of the second National Health and Nutrition Examination Survey, 1976-1980. Washington, DC: U.S. Gov Pr Office; 1981; DHHS publication no. (PHS) 81-1317.
5. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-8.
6. National Center for Health Statistics. Cycle I of the Health Examination Survey; sample and response. United States, 1960-1962. Washington, DC: U.S. Gov Pr Office; 1964.
7. U.S. Bureau of the Census. U.S. population estimates, by age, sex, race, and Hispanic origin: 1990 to 1994. Washington, DC: U.S. Bureau of the Census; 1994.
8. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.
9. McIsaac WJ, Naylor CD, Basinski A. Mismatch of coronary risk and treatment intensity under the National Cholesterol Education Program guidelines. J Gen Intern Med. 1991;6:518-23.
10. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009-14.
11. Hunninghake DB, Stein EA, Dujovne CA, Harris WS. Feldman EB. Miller VT, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 1993;328:1213-9.
12. Neil HA, Roe L, Godlee RJ, Moore JW, Clark GM, Brown J, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ. 1996;310:569-73.
13. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ. 1991;303:953-7.
14. Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American aspirin studies [Letter]. N Engl J Med. 1988;318:923-4.
15. Manson JE, Stampfer MJ, Colditz GA, Willet WC, Rosner B, Speizer FE, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521-7.
16. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
17. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
18. Drug Topics Red Book. Montvale, NJ: Medical Economics Co.; 1995.
19. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-83.
20. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992;304:431-4.
21. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-8.
22. Hulley SB, Walsh JM, Newman TB. Health policy on blood cholesterol. Time to change directions [Editorial]. Circulation. 1992;86:1026-9.